
Research
New AIDA Network collaborative study: Upadacitinib for the treatment of uveitis
A new collaborative study has been launched within the AIDA Network to investigate the efficacy and safety of upadacitinib in patients with uveitis.
Patients with any anatomical type of uveitis (anterior, intermediate, posterior uveitis or panuveitis) may be included, whether idiopathic or associated with systemic diseases, including ankylosing spondylitis, psoriatic arthritis, Behçet’s disease, sarcoidosis, Crohn’s disease, and many other systemic inflammatory conditions.
Patients should be enrolled in the AIDA Network Uveitis Registry, except for those with Behçet’s disease-associated uveitis, who should be included in the AIDA Network Behçet’s Disease Registry.
Colleagues are warmly invited to contribute patient data by December 15, 2026, after which data analysis will begin.